AUS
NZ
UK
CA
USA
IND
Cannabis
Why Cash Runway Matters More Than Ever for ASX Cannabis Stocks
June 18, 2026 10:39 AM AEST| By SamAustralia's cannabis sector is evolving as investors place greater emphasis on cash runway, commercial execution and sustainable growth, shifting attention away from expansion narratives and towards long-term business performance.
Medicinal Cannabis Shares Meet A Stricter Export Check
June 18, 2026 10:39 AM AEST| By SamCannabis stocks face a sharper export quality test as medicinal access, product standards, revenue durability and funding discipline become central to the latest ASX sector story.
ASX 200 Cannabis Stocks Face A Revenue Test
June 18, 2026 10:39 AM AEST| By SamCannabis stocks remain under review as regulated access, medicinal demand, export revenue and capital discipline shape whether ASX operators can close the gap between sector interest and commercial scale.
Neurizon Therapeutics (ASX NUZ) Shares Jump After Elanco Supply Deal
June 17, 2026 02:30 AM AEST| By Sonal Goyal
ASX Cannabis Stocks: Why the Medicinal Access Filter Matters
June 17, 2026 03:04 PM AEST| By SamAustralia's medicinal cannabis sector is drawing renewed attention as markets focus on patient access, regulatory pathways and commercial execution. Companies with stronger revenue visibility, financial discipline and healthcare integration are becom...
ASX Cannabis Stocks: Cash Runway Reality Takes Centre Stage
June 17, 2026 02:54 PM AEST| By SamAustralian cannabis stocks are back in focus as investors assess cash runway, manufacturing scale, balance-sheet strength and operational execution. Companies with sustainable growth pathways are attracting the greatest market attention.
ASX 200 Cannabis Stocks Shift Toward Clinical Proof
June 17, 2026 11:07 AM AEST| By SamASX 200 cannabis stocks are increasingly shaped by clinical evidence as research-backed cannabinoid therapies support medical adoption, regulatory acceptance and global expansion across structured healthcare markets.
Island Pharmaceuticals (ASX:ILA) Advances Galidesivir Program with New FDA Recognition
June 17, 2026 02:13 AM AEST| By Aditi SarkarIsland Pharmaceuticals Ltd (ASX:ILA) traded higher during the morning session on 17 June 2026, rising 1.41% to AUD 0.36 after announcing a regulatory milestone for its Galidesivir antiviral program. The company revealed that the United States Food and Drug Administration (FDA) has granted Orphan …
ASX Cannabis Stocks Face Reality Check in 2026
June 17, 2026 11:06 AM AEST| By SamASX cannabis stocks are entering a more mature phase where revenue, compliance and execution now define success, with Little Green Pharma and Cann Group reflecting the industry’s evolving commercial focus.
Cannabis Merger Shock Reshapes ASX Growth Story
June 17, 2026 11:06 AM AEST| By SamLittle Green Pharma’s merger with Cannatrek highlights growing consolidation in the Australian medicinal cannabis sector, with emphasis on manufacturing scale, regulated compliance and expanding European export opportunities.
ASX Cannabis Exports Drive Growth in Global Markets
June 17, 2026 04:21 AM AEST| By SamASX cannabis companies are expanding into Europe, with export-led growth reshaping sector structure and strengthening international supply chain integration.
Is Inoviq (ASX:IIQ) Emerging as a Healthcare Stock to Watch?
June 16, 2026 06:16 PM AEST| By Aditi SarkarInoviq Ltd (ASX:IIQ) delivered a strong performance on 17 June, with the healthcare stock advancing 27.12% to AUD 0.38. The company added AUD 0.080 during the session, with buying interest pushing the stock from its opening price of AUD 0.31 to an intraday high …
Cash Runway Takes Centre Stage for ASX Cannabis Stocks
June 16, 2026 03:00 PM AEST| By SamASX cannabis stocks are entering a more disciplined phase as investors focus on funding strength, operational execution and sustainable commercial growth.
Export Standards or Scale? The New Challenge Facing Cannabis Stocks
June 16, 2026 03:00 PM AEST| By SamASX cannabis stocks are increasingly being assessed on export readiness, operational execution and commercial scale as the medicinal cannabis sector continues to mature.
Regulatory Reality: Why Cannabis Stocks Are Back on Investors’ Watchlists
June 16, 2026 03:00 PM AEST| By SamASX cannabis stocks are being increasingly assessed through patient access, regulatory compliance, distribution strength and commercial execution as investors become more selective.
Could Vitasora Health (ASX:VHL) Revisit Its 52-Week High?
June 16, 2026 06:15 PM AEST| By Aditi SarkarVitasora Health Ltd (ASX:VHL) emerged among the notable gainers on 17 June after its shares advanced 28.57% to close at AUD 0.018. The stock added AUD 0.004 during the day, with buying momentum pushing the price from an opening level of AUD 0.015 to …
Little Green Pharma (ASX:LGP) Bulks Up as Cannatrek Merger Completes
June 16, 2026 11:35 AM AEST| By SamLittle Green Pharma completes its Cannatrek merger, strengthening vertical integration and scale as the ASX cannabis sector continues consolidating toward revenue-focused, regulated and operationally disciplined businesses.
ASX Cannabis Stocks 2026: Revenue Now Leads Sector Shift
June 16, 2026 11:35 AM AEST| By SamASX cannabis stocks are entering a more disciplined phase where revenue, execution and regulatory compliance matter more than speculation, reshaping how investors view the sector.
Telix's New Healthcare Collaboration Sparks Fresh Market Discussion
June 16, 2026 10:43 AM AEST| By SamTelix Pharmaceuticals strengthened its precision medicine strategy through a new healthcare collaboration that combines imaging technologies, artificial intelligence tools, and theranostic workflows.
Pro Medicus (ASX: PME) Joins June Healthcare Rotation as Investors Hunt Quality Growth
June 16, 2026 05:54 PM AEST| By Aditi SarkarHighlightsPro Medicus (ASX: PME) is featuring in a June 2026 healthcare rotation as investors look toward quality-growth names in the sector.The company is a leading provider of medical imaging software, known for its radiology and visualisation technology used by hospitals and health systems.A rotation …
Why ASX Cannabis Stocks Are Back on Investor Watchlists
June 15, 2026 05:41 PM AEST| By SamASX cannabis stocks are back in focus as clinical credibility, cash-flow discipline, and regulatory developments shape investor attention across the healthcare sector amid evolving market conditions.
Cannabis Stocks in Focus as Export Quality Shapes Market Attention
June 15, 2026 03:56 PM AEST| By SamASX cannabis stocks are under the spotlight as export quality, revenue discipline, and operational execution emerge as key themes shaping sector sentiment amid a strengthening Australian market backdrop.
Cannabis Stocks in Focus: Can Strong Execution Sustain Market Attention?
June 15, 2026 03:48 PM AEST| By SamASX cannabis stocks are back in focus as market sentiment improves, with attention centred on patient access, export opportunities, cash management and operational execution across the sector.
Dimerix (ASX: DXB) Lands Major Asia Deal for DMX-200 Kidney Disease Treatment
June 16, 2026 03:18 PM AEST| By Aditi SarkarHighilghtsDimerix (ASX: DXB) has secured a major Asia licensing deal for its lead kidney-disease candidate DMX-200, with Everest Medicines named as the commercial and licensing partner for the region.DMX-200 is being developed for focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease with …
ASX Cannabis Stocks Face a New Reality in 2026: Proof Over Promise Takes Control
June 15, 2026 12:24 PM AEST| By SamASX cannabis stocks are moving into a more disciplined phase in 2026, where revenue generation, regulatory compliance and clinical credibility now define market value and investor focus.
Exporting the Green: How ASX Cannabis Shares Are Chasing Global Medicinal Demand
June 15, 2026 12:24 PM AEST| By SamAustralian medicinal cannabis producers are expanding into global markets, with export demand, European healthcare systems, and manufacturing standards reshaping the growth outlook for ASX-listed sector participants.
Advertise your brand on Kalkine Media